CEO of BioOrbit, a company building a pharmaceuticals factory in microgravity to revolutionise cancer treatment. BioOrbit aims to bring a paradigm shift to the administration route of cancer treatments. Much like diabetics self-inject with solutions of crystalline insulin, through crystallising antibodies in microgravity, subcutaneous derivatives of anticancer treatments can be formulated, enabling cancer sufferers to self-inject at home. She is a strong believer that science in a microgravity environment can be used to accelerate healthcare and drug development on Earth, and recently won the ‘Innovator Award 2024’ at Everywoman in Tech Awards and Codex World top 50 Innovators ‘Top Female Innovator’ . Katie completed her PhD in nanomedicine at the University of Cambridge in 2022, has worked at NASA, AstraZeneca and spent several years as an RAF volunteer reservist. Her vision is to see BioOrbit as the go-to manufacturing line and research facility in microgravity.